Global Genitourinary Partnering Directory 2010-2020: Deal Trends, Players and Financials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Genitourinary Partnering 2010-2020: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

Global Genitourinary Partnering 2010 to 2020 provides the full collection of Genitourinary disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Report scope

Global Genitourinary Partnering 2010 to 2020 includes:

  • Trends in Genitourinary dealmaking in the biopharma industry since 2010
  • Analysis of Genitourinary deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genitourinary deal contract documents
  • Comprehensive access to over 500 Genitourinary deal records
  • The leading Genitourinary deals by value since 2010
  • (Read more…)

  • Most active Genitourinary dealmakers since 2010

The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie’s disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.

Available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Genitourinary dealmaking

2.1. Introduction

2.2. Genitourinary partnering over the years

2.3. Genitourinary partnering by deal type

2.4. Genitourinary partnering by industry sector

2.5. Genitourinary partnering by stage of development

2.6. Genitourinary partnering by technology type

2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering

3.1. Introduction

3.2. Disclosed financials terms for Genitourinary partnering

3.3. Genitourinary partnering headline values

3.4. Genitourinary deal upfront payments

3.5. Genitourinary deal milestone payments

3.6. Genitourinary royalty rates

Chapter 4 – Leading Genitourinary deals and dealmakers

4.1. Introduction

4.2. Most active in Genitourinary partnering

4.3. List of most active dealmakers in Genitourinary

4.4. Top Genitourinary deals by value

Chapter 5 – Genitourinary contract document directory

5.1. Introduction

5.2. Genitourinary partnering deals where contract document available

Chapter 6 – Genitourinary dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Genitourinary therapeutic target


Appendix 1 – Directory of Genitourinary deals by company A-Z 2010 to 2020

Appendix 2 – Directory of Genitourinary deals by deal type 2010 to 2020

Appendix 3 – Directory of Genitourinary deals by stage of development 2010 to 2020

Appendix 4 – Directory of Genitourinary deals by technology type 2010 to 2020

For more information about this report visit https://www.researchandmarkets.com/r/bqjzz4



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.